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Abstract 
Oral route of administration have wide acceptance up to 50-60% to total drug 
forms. Fast disintegrating drug delivery system has number of advantage 
such as faster onset of action, attractive elegance, ease of administration. In 
this study, an attempt has been made to study direct compression method, for 
formulation of fast disintegrating tablets of Isoniazid and Rifampicin, an anti-
tubercular drug in view of enhancing bioavailability. These formulations 
have sufficient hardness and can be manufactured by commonly used 
equipment.  Prior to formulation the pre-compression parameters were 
characterized for flow properties and prepared formulations were evaluated 
for physico-chemical parameters, X-ray powder crystallography, SEM and 
in-vivo bioavailability. All four formulations possessed good disintegration 
properties with total disintegration time of 25 to 40 seconds. The effects of 
different superdisintegrants and process variables on drug release profile and 
disintegration property were evaluated and results revealed the better drug 
release with different superdisintegrants such as Ac-di sol and Polyplastadone 
XL. All formulations are rapidly disintegrated in oral cavity as well as all 
formulations possess good anti-tubercular properties. SEM Showed the 
mechanical strength of the formulations affected the morphological changes 
after compression. Hence, it is evident from this study that fast dispersible 
tablets could be a promising delivery system for Isoniazid, Rifampicin and 
their combination with good mouth feel and improved drug availability with 
better patient compliance.    
 
Keywords: Isoniazid; Rifampicin; Superdisintegrants; Direct compression 
method; Bioavailability. 
. 
Introduction  
Oral administration is the most popular route among 
all the routes to ease ingestion, pain avoidance, 
versatility (to accommodate various types of drug 
candidates) and most importantly patient compliance 
[1], Dispersible tablets are uncoated tablets that 
produce uniform dispersion in water. The rate of 
absorption of a drug from a tablet depends upon its 
ability to disintegrate quickly and dissolve.  
 
Dispersible tablets have found wide acceptance today 
replace conventional suspension and dry syrap dosage 
form [2]. Recently pharmaceutical industry has 
become increasingly aware of the need that elderly be 
considered as a separate and unique medicare 
population. Thus, oral dispersible tablets are gaining 
more demand and popularity from last few years [3]. 
Isoniazid is chemically 4-Pyridinecorboxylic acid 
 doi:10.5138/ijdd.2010.0975.0215.02044 
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hydrazine, and the usual daily dose is 300 gm daily. 
Isoniazid is used in the treatment of primary treatment 
of pulmonary and extra pulmonary tuberculosis. 
Rifampicin is chemically (12Z,14E,24E)-(2S,16S, 
17S, 18R, 19R, 20R, 21S, 22R, 23S)- 1,2 dihdro-
5.6.9, 17, 19- heptamethyl-8-(4-methyl-peprazine-1-
yliminomethyl)-1,11,13-triemino)neptho[2,1-b] furan 
21-yl acetate and the usual daily dose is 4500 gm 
daily. IsoRifampicin is used in the treatment of 
primary treatment of pulmonary and extra pulmonary 
tuberculosis. Ac-di-sol is basically cross linked 
sodium carboxymethyl cellulose and this is used in 
oral pharmaceutical formulations as a disintegrant for 
capsules, tablet and granules. Polyplasdone XL is 
chemically 2-pyrrolidinone, 1-ethyl-homopolymer1-
vinyl-2-pyrrolidinone-polymer and pharmaceutically 
this is used as superdisintegrant, tablet binder, 
sweetening agent and pharmaceutical excipients. 
Explotab is chemically starch carboxymethyl ether, 
sodium salt and this is used as a disintegrant in 
tablet/capsule formulation [4-6]. 
Tuberculosis is an infectious disease caused by 
several species of mycobecteria. M. Tuberculosis is a 
slender, or slightly curved bacillus, ranging from 1-4 
µm length, they are acid-fast bacilli. 31 Oral 
tuberculous lesions may be either primary or 
secondary. Primary oral tuberculous lesions are 
extremely rare and generally occur in younger 
patients associated with cervical lymphadenopathy. 
The primary lesion remains painless in the majority of 
cases. The secondary lesions, on the contrary, are 
more common and are seen mostly in older persons. 
The lesions are seen as superficial ulcers, patches 
indurated soft tissue lesions, or even lesions in the 
jaws that may be in the form of tuberculous 
osteomyelitis, or simple bony radiolucencies. Of all 
these oral lesions, the ulcerative form is the most 
common and is often painful with no associated 
caseation of the dependent lymph nodes [7-10] 
An attempt has been made, in the present work, to 
develop dispersible tablet of Rifampicin by direct 
compression method, using a bland of disintegrants 
such as crosscarmellose sodium (Ac-di-sol) and 
Polyplasdone XL. The objectives of the study were to 
investigate the performance of superdisintegrants and 
effect of other process variables on the characteristics 
of the Isoniazid and Rifampicin dispersible 
formulations. 
Isoniazid and Rifampicin were procured from 
Macload Pharmaceuticals Ltd, Mumbai, India. 
Polyplasdone XL ware procured from Sun 
Pharmaceuticals Ltd, Baroda, Gujarat, India. 
Crosscarmellose sodium (Ac-di-sol) sample was 
obtained from FMC Biopolymer, USA and Explotab 
(SSG) sample was procured from Forum Biosciences, 
England (U.K.). All other Chemicals and solvents 
were of analytical grade and purchased from local 
market in India. 
 
Preparation of combination dispersible 
formulations [11,12] 
Different Isoniazid and Rifampicin combination 
dispersible formulations were prepared by direct 
compression technique according to the formula 
given in table 1.  
 
Table 1. Composition of INH and Rifampicin 
combination dispersible formulations. 
 
Ingredients F1 F2 
Isoniazid 100 100 
Rifampicin 100 100 
Avicel pH102 108 108 
Ac-di-sol 17.5 -- 
Polyplasdone XL -- 17.5 
Mannitol 17.5 17.5 
Sodium Saccharine 7 7 
Magnesium Stearate 7 7 
Flavor 4 4 
 
Blank space indicate that those components 
not present in the formulations 
 
The concentration of disintegrants was developed as 
optimal concentration under experimental formula 
and conditions of preparation. A total of 6 
formulations were prepared. All the ingredients were 
passed through 60 mesh sieve separately and 
collected. The drug and Avicel pH 101 were mixed in 
a small portion of both and each time blended to get a 
uniform mixture in a geometrical order. The tablets 
were then compressed using 10 mm size punches to 
get a tablet of 100 mg Rifampicin and 100 mg 
Isoniazid using hydraulic press with suitable standard 
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punches and stored in a well-closed container till use. 
In the first set 2 batches of Isoniazid and Rifampicin 
fast dispersible tablets were prepared using different 
concentration of sodium starch glycolate and other 
super disintegrants. 
 
Evaluation parameters of combination dispersible 
formulations 
a) Pre-compression parameters [13] 
i) Bulk density:- Both loose bulk density (LBD) and 
tapped bulk density (TBD) were determined. 
Accurately weighed amount of sample (20 gm) was 
transferred into a 25 ml measuring cylinder. The 
volume of packing was recorded. The measuring 
cylinder was then tapped 100 times on a plane hard 
wooden surface and the tapped volume of packing 
was recorded. LBD and TBD were calculated by the 
following formula: 
 
LBD (Loose bulk density)  =  Weight of granules 
                                   Volume of packing  
 
TBD (Tapped bulk density) =    Weight of granules  
                              Tapped volume of packing  
 
ii) Compressibility index:- Percent compressibility 
of granules as determined by Carr’s compressibility 
index was calculated by the following formula: 
         Carr’s Index   =   TBD – LBD    x    100 
                         TBD 
 
iii) Angle of repose (θ):- The frictional forces in a 
loose powder or granules can be measured by angle of 
repose. This is the maximum angle possible between 
the surface of a pile of powder or granules and the 
horizontal plane. 
The granules were allowed to flow through the funnel 
fixed to a stand at definite height (h). The angle of 
repose was then calculated by measuring the height 
and radius of the heap of granules formed. 
           Tan θ  = h/r 
           θ = tan -1 (h/r) 
Where θ = Angle of repose,  h = height, r = radius  
Values of angle of repose ≤30° indicate free flowing 
granules and ≥40° suggest poorly flowing material.  
 
b) Post-compression parameters [14-17]: 
i) Thickness and diameter:- The tablet dimensions 
were measured using a calibrated dial caliper. 5 
tablets of each batch were picked randomly and its 
thickness and hardness were measured individually. 
Tablet thickness should be controlled within ±5 % 
variation of a standard value. 
 
Table 2.  Pre-compression parameters: 
characterization of formulation powder  
 
Formula-
tions 
Angle 
of 
Repose 
(θ) 
Loose 
Bulk 
Density 
(gm/cm3) 
Tapped 
Bulk 
Density 
(gm/cm3) 
% 
Compre-
ssibility 
Appea-
rance 
F1 29.32 0.57 0.68 16.17 Reddish 
white 
F2 27.01 0.55 0.64 14.06 Reddish 
white 
 
ii) Weight Variation:- The procedure described in IP 
1996 was employed to determine the weight variation 
of the tablets. Ten tablets were randomly selected 
from each batch and weighed on a electronic balance 
and the mean weight taken. Each tablet was then 
weighed individually and the standard deviation in 
weight was calculated for each batch.  
 
iii) Hardness:- Hardness indicates the ability of a 
tablet to withstand mechanical shocks while handling. 
The hardness of the tablets was determined using 
Monsanto hardness tester. It is expressed in kg/cm2. 
Five tablets were randomly picked from each batch 
and the hardness of the tablets was determined. The 
mean and standard deviation values were calculated 
for each batch.  
 
iv) Friability:- Friability of the tablets were 
determined using Roche friabilator. It is expressed in 
percentage (%). Ten tablets were initially weighed 
(Winitial) and placed into the friabilator. The friabilator 
was operated at 25 rpm for 4 minutes or run up to 100 
revolutions, and then the tablets were weighed again 
(Wfinal). The loss in tablet weight due to abrasion or 
fracture was the measure of tablet friability.  
% Friability was then calculated by :- 
   F =  W(initial) – W(final)    x   100 
                        W(initial) 
% Friability of less than 1% is considered acceptable. 
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Table 3.  Post-compression parameters: evaluation of tablets. 
 
Formulation 
Code 
Uniformity of 
Thickness* (mm) 
Hardness* 
(kg/cm3) 
Weight**  
 (mg) 
Drug Content 
Uniformity* (mg) 
Friability 
(%) 
Test of 
dispersion 
F1 2.278±0.0647 4.63±0.13 361±2.36 97.27±0.47 0.67 Passed 
F2 2.238±0.098 4.48±0.04 361±2.86 99.06±0.21 0.65 Passed 
 
*Tests performed, n=3,**Tests performed, n=10 
 
 v) Disintegration test: - Introduced one tablet in to 
each tube. The disc was added to each tube. The 
assembly was suspended in Beaker containing buffer 
and operated the apparatus for 3 mim. Water is used 
as medium at temperature of 26°C.  
 
Table 4.  Post-compression parameters: wetting 
time, water absorption  ratio (mean±SD, n=3). 
 
vi) Uniformity of dispersion: - this test is applicable 
only for dispersible tablets. Placed 1 tablet in 100 ml 
of water and stirred gently until completely dispersed. 
A smooth dispersion was obtained which passes 
through a sieve screen with a nominal mesh aperture 
of 710 μm (Sieve no. 22). 
 
vii) In-vitro dissolution study [18-20]: In-vitro 
dissolution study were carried out on USP XXIII 
tablet dissolution apparatus using pH 6.8 buffer 900 
ml at 100 rpm for 20 min at 37°C, employing paddle 
method . Single tablet from each formulation was 
used for the studies. A 1ml sample from dissolution 
medium was withdrawn at different time intervals and 
diluted approximately so as to get a concentration of 
10 μg/ml.  The withdrawn sample was replaced by 
same amount of fresh dissolution medium to maintain 
sink conditions. The absorbance was measured on UV 
Spectrophotometer at 261 nm. 
viii) Scanning electron microscopy [21] :  SEM has 
been used to determine particle size distribution, 
surface topography, texture and to examine the 
morphology of fractured or sectioned surfaces. The 
SEM is most commonly used for generating three 
dimensional surface relief images derived from 
secondary electrons. The examination of the surface 
of polymeric drug delivery systems can provide 
important information about the porosity and 
microstructure of the device.  
 
Table 5.   Post-compression parameters: in vitro 
dispersion time, dissolution report. 
 
 
ix) Powder X-ray diffraction [22,23]: The powder 
X-ray diffraction measurement were conducted over a 
5-40º 2Ǿ range on a Siemans model D5000 
diffractometer, equipped with monochromatic CuKα 
(α1= 1.54060 A, α2=1.54438A) X-ray. The step 
width was 0.020º 2θ/min with a time constant of 0-5 
sec. the integration of the crystalline reflections was 
achieved using the Diffracplus diffraction softwere 
(Eva, version 2.0, Siemans Energy and automation, 
Inc. Madison, WI). The degree of crystallinity of 
samples was expressed as the percentage ratio of the 
integrated intensity of the sample to that of 
hydrocellulose, a crystalline standard prepared from 
cellulose by treating with 2.5 N HCl at boiling 
temperature. 
Formulation 
Code 
Wetting Time 
(Seconds) 
Water 
Absorption 
Ratio 
F1 224.76 ± 1.48 25.14 ± 1.76 
F2 224.58± 1.67 24/.98 ±1/54 
Formulation 
Code 
Disintegration 
Time (Second) 
Dispersion 
Time 
(Second) 
% Drug 
release 
F1 27.52 ± 1.72 146.76 ± 1.0 INH-99.99 RIFA-90.35 
F2 28.43 ± 1.14 172.16± 0.86 INH-96.72 RIFA-87.18 
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x) Stability study [24,25]:  The purpose of stability 
testing is to provide evidence on how the quality of a 
drug substance or drug product varies with time under 
the influence of a variety of environmental factors 
such as temperature, humidity and light, and enables 
recommended storage conditions and shelf-lives to be 
established.  
ICH specifies the length of study and storage 
conditions:- 
Long term testing 250c±20c/60% RH ±5% for 12 
months, 
Accelerated testing 400c±20c/75% RH ±5% for 6 
months. 
 
Table 6.  Anti-tubercular activity of isoniazid, 
rifampicin and combination dispersible 
formulations. 
 
xi) Biodistribution study [26-28]: 
Isoniazid and Rifampicin combination tablets 
In vivo studies were conducted using albino rats 
(Wister Rats) and the plasma concentration time 
profile of Isoniazid and Rifampicin combination was 
determined using UV spectrophotometry. In this 
study, Isoniazid and Rifampicin combination 
dispersible tablets administered orally to rats and 
every 30 minute drug concentration were determined 
in serum. The method used for determination is as 
follows: 
 
Extraction procedure for Isoniazid 
Albino Rats (Wister Rats) were divided in 7 groups. 
One group was kept as a control. 6 groups of animal 
were given Isoniazid dispersible tablet prepared in 
PBS. Drug solutions were administered through the 
oral route with the help of canula. The blood samples 
were collected from retro-orbital eye plexus. All 
blood samples were centrifuged at 3000 rpm for 15 
min. The supernatant (plasma) was deproteinized by 
adding acetonitrile (1 ml/ml of plasma). The samples 
were again centrifuged and 2 ml of these supernatant 
was diluted to 10 ml with PBS pH 7.4. Then 1 ml of 
this diluted blood serum was then made up to the 
mark (10 ml) with PBS, then analyzed  
spectrophotometrically at 266 nm for drug content 
against a similarly treated blood sample of control 
rats after proper dilution. The observations are 
recorded and drug content in the plasma was 
determined.  
 
Table 7.  In vivo bioavailability studies of isoniazid 
from combination formulation (f-1) and free drug 
in blood. 
 
Isoniazid 
dispersible 
tablet 
Pure Isoniazid 
No. of 
animals Drug 
content 
(mg) 
% 
Drug 
content 
Drug 
content 
(mg) 
% 
Drug 
content 
1 0.52 20 0.42 16.15 
2 0.48 18.46 0.4 15.3 
3 0.51 19.61 0.35 13.46 
4 0.49 18.84 0.41 15.76 
5 0.50 19.2 0.35 13.46 
Mean - 19.22 - 14.82 
+SE  0.3005  0.2887 
p value p<0.0001 
 
Isoniazid DT was compared with pure Isoniazid 
group applying student ‘t’ test. Dose Injected Per 
Mice-2.6 mg 
 
Extraction procedure for Rifampicin 
Albino Rats (Wister Rats) were divided in 7 groups. 
One group was kept as a control. 6 groups of animal 
were given Rifampicin dispersible tablet prepared in 
PBS. Drug solutions were administered through the 
oral route with the help of canula. The blood samples 
were collected from retro-orbital eye plexus. A 0.5 ml 
aliquot of sample (plasma sample) was added 2 ml of 
0.5M sodium dihydrogen phosphate. The mixture was 
shaken mechanically with 7 ml of chloroform for 10 
min. after centrifugation at 3000 rpm for 15 min, the 
upper aqueous phase was aspirated off using syringe 
and 5 ml of the lower organic phase were taken to 
dryness at 40 ºC under reduced pressure. The residue 
was dissolved in 0.5 ml of the mobile phase and 
Rifampicin level was determined using UV 
spectrophotometry at 340 nm. Both drugs are 
extracted separately and analyzed as per above 
described methods separately. 
Zone of inhibition at different drug 
concentration 
Test 
compound 
100 µg 300 µg 
F1 No growth No growth 
F2 No growth No growth 
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Results and discussion 
The FTIR spectra of pure Isoniazid indicated the 
characteristic absorption stretch for Strong C=O 
Stretch band (Amide II) at 1560 cm -1 and broad 
bands between 3300 and 3000 cm -1 for bonded N-H 
and C-H, stretch are obtained. The finger point region 
FTIR spectra showed a characteristic sharp peak at 
1670 and 1610, 1500 cm -1 for C=O, ring C=C and 
C=N. In comparison with the pure Isoniazid, the 
absorption peak of the spectra for Isoniazid in its 
formulations showed no shift and no disappearance of 
characteristic peaks suggest that there is no 
interaction between Isoniazid and other additives. No 
degradation of Isoniazid molecule was observed 
during its formulation development, hence the drug-
excipient combinations used in the formulation 
development were compatible under given set of 
experiments (Figure 1). 
 
 
(a) 
(b) 
 
(c) 
 
(d) 
 
Figure 1. FTIR study of the prepared rifampicin dispersible formulations (a) pure isoniazid (b) pure 
rifampicin (c) Formulation F-1 (d) Formulation F-2. 
 
327
Shukla et al. International Journal of Drug Delivery 2 (2010) 322-332 
 
 
 
Similarly, the FTIR spectra of pure Rifampicin 
indicated the characteristic absorption stretch for C=O 
group at 1572 cm -1 and broad bands for N-H stretch 
was obtained between 2800 and 2300 cm-1. The finger 
print region of FTIR spectra showed a characteristic 
sharp peak at 1281 and 1040 cm -1 for C-O-C acetyl 
group. In comparison with the pure Rifampicin, the 
absorption peak of the spectra for Rifampicin in its 
formulations showed no shift and no disappearance of 
characteristic peaks suggest that there was no 
interaction between Rifampicin and other additives or 
no degradation in Rifampicin molecule during 
formulation development (Figure 1) . 
The result of angle of repose was found to be in the 
29°.32’ and 27°.01’. Both formulations showed angle 
of repose within 30° which indicates good flow of 
powder mixture. Angle of repose little higher above 
30° is indicative of fair flow behavior of powder, The 
loose bulk density and tapped bulk density for both 
formulations varied from 0.57 gm/cm3 to 0.55 
gm/cm3 and 0.68 gm/cm3 to 0.64 gm/cm3 
respectively. The values obtained lies within the 
acceptable range and not large differences found 
between loose bulk density and tapped bulk density. 
The percent compressibility for all the four 
formulations lies within the range of 16.17 and 14.06. 
All formulations showed good compressibility hence 
can be directly compressed (Table 2). 
Table 3 depicts the physical parameters (hardness, 
weight variation, thickness, drug content and 
friability) and drug content of all fabricated tablets. 
Table 4 reflects the wetting time and uniformity of 
dispersion of these tablets. All the tablet formulation 
showed acceptable pharmaco-technical properties and 
complied with pharmacopoeial specification for 
weight variation, drug content (%), friability, 
disintegration and uniformity of dispersion (UOD). 
Hardness was maintained to be within 4.48 kg/cm2 to 
4.63 kg/cm2. Since fast disintegrating tablets are less 
hard then conventional ones, due to a lower 
compression employed (Hardness is usually 3KPa.), 
these tablets can therefore be fragile and need 
individual packaging.  The lower standard deviation 
values indicated that the hardness of all the 
formulations were almost uniform in specific method 
and possess good mechanical strength with sufficient 
hardness. To obviate the difference in the hardness, 
superdisintegrants are added in the formulations. In 
fact, a fast disaggregating tablet must disintegrate in 
the saliva; harder tablets need a de-aggregating agent 
of a superior ability. In this case Ac-Di-sol, and 
polyplastadone XL were employed. Tablet 
disintegration was affected by the wicking and 
swelling of the disintegrant, and the wicking property 
would be closely related to the pososity. Both the 
porosity and average pore size of tablets in all 
formulation decreased with increase of the tablet 
hardness.  
 
__                                                                                  
 
 
 
 
Figure 2. (a)  plot of cumulative % drug released 
vs time for INH in different combination 
formulations (zero order plot). (b) plot of 
cumulative % drug released vs time for rifampicin  
in different combination formulations (zero order 
plot). 
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The wicking property may also correlate to the 
wetting behavior of the tablet. Rapid dispersion 
within seconds has been observed in all the 
formulations. On the basis of the de-aggregation time 
of the tablets, according to the EP IV Ed., almost all 
the formulations developed can be defined “Fast 
dispersible”: the limit for de-aggregation is in fact 
suggested as within 3 min. The direct compressed 
tablets consumes less wetting time and all formulation 
passes test for dispersion. 
 
 
        
 
Figure 3. Scanning electron microscope (SEM) study of the prepared dispersible formulations. (a) and (b) 
are of F-1 formulation; (c) and(d) areof F-2 formulation. 
 
The high ratio of water absorption was found in tablet 
containing disintegrants such as crosscarmellose 
sodium (Ac-di-sol), Polyplasdone XL, which is due to 
hydrophilicity and swelling capacity. All formulated 
dispersible tablets gave faster and rapid dissolution of 
Rifampicin. The results are reported in table 5 and 
formulations follow zero order release kinetics. The 
graphs were plotted as time Vs percentage (Figure 
no.2) drug release for all the formulations. Among all, 
the tablet formulated by employing Explotab (SSG) 
disintegrated rapidly and gave faster dissolution of 
Isoniazis(INH) and  Rifampicin (RIFA).  
All formulations were subjected to Scanning Electron 
Microscopy (SEM) to examine the surface 
topography, texture of the formulations, morphology 
of fractured or sectioned surfaces, that can provide 
important information about the porosity of the device 
in the matrix of the formulations by subjecting the 
formulations to SEM in dry state at the different 
magnifications, X500, X1000  using a JEOL JSM-
T330A. SEM images are shown in figure no.3.  After 
examination the photographic results obtained from 
SEM, it was observed that formulation F2, contained 
particles of similar microscopic geometric which 
reflects the particles sizes of the parent potato 
starches of the range of 10-100 µm. Additionally, 
examination at higher magnification suggested that 
the surfaces of the particles contained small, micron 
size, features. However, in case of Ac-di-sol 
formulations (F1) no cracks were observed, 
suggesting that the formulations had good mechanical 
properties. The small increase in drug release may not 
necessarily be attributed to surface rupturing or creak 
formation.  
The particles on the tablet surface were more 
compressed then those inside, there existed many 
empty spaces between the particles throughout the 
tablet where water could be absorbed by capillary 
forces. At higher magnification, a detailed 
distribution of pores can be observed. Upon contact 
with water or saliva, the particles could easily 
dissociate, and the whole tablet disintegrated to form 
a paste, which is easy to swallow. As the compression 
pressure increased, the pores become smaller. The 
porous structure of the tablet was especially hard to 
observe.  
X-ray powder diffractometry (XRPD) is a powerful 
technique for the identification of the crystalline solid 
phases. Every crystalline solid phase has a unique 
XRPD pattern, which can form the basis for its 
identification. The X-ray powder diffraction (XRD) 
spectra of Rifampicin showed characteristic 
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diffraction peaks in the 8.84º, 7.30º, 5.25º, 2θ 
Characteristic peaks of Rifampicin were detectable in 
the formulations (F-1 to F4). It is very difficult to 
identify the presence of Avicel pH 102 or 
superdisintegrants in the XRPD spectra as they are 
polymers with amorphous structure and no sharp 
peaks are apparent at particular 2θ, due to the very 
low crystallinity of these components.    
 
 
 
(a) 
 
(b) 
 
(c) 
 
(d) 
 
Figure 4. XRD study of the prepared rifampicin dispersible formulations(a) pure isoniazid (b) pure 
rifampicin (c) Formulation F-1 (d) Formulation F-2. 
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X-ray powder differection spectras are shown in XRD 
able 8.  In vivo bioavailability studies of 
Rifampicin 
Pure rifampicin 
 
Figure No.4. The anti-tubercular activity of the 
formulations is investigated in the Lawenstain- 
Jensen’s medium (L.J. medium). H37Rv strain is used 
for the anti-tubercular activity and formulations are 
evaluated in two concentrations i.e. 100 µl and 300 
µl. The result indicates that all formulation active 
against the H37Rv strain, and possess the anti-
tubercular activity.  
 
T
rifampicin from combination formulation (F-1) 
and free drug in blood. 
 
dispersible 
tablet No. of 
t 
% 
g 
t 
Drug 
t 
% 
g 
t 
animals Drug 
conten
(mg) 
Dru
conten
conten
(mg) 
Dru
conten
1 0.46 17.6 0.35 13.46 
2 0.43 16.53 0.37 14.2 
3 0.48 18.46 0.34 13.07 
4 0.46 17.69 0.36 13.84 
5 0.44 16.92 0.32 12.30 
Mean - 17.44 - 13.37 
+SEM - 0.5568  - 0.3536
p value p<0.0001 
 
Rifampicin DT was compared with pure Isoniazid 
 
he result of screening is tabulated in table 7. The 
average bioavailability of Isoniazid from combina  
ng disintegration agents 
eod Pharmaceuticals Ltd, 
iding gift sample of 
. Indurwade NH, Rajyaguru TN, Nakhat PD. Novel 
Fast Dissolving Tablets. Indian drugs 
 systems for elderly. Indian 
. Formulation study of 
 Pharma Sci 2004; 66: 
350-353. 
group applying student ‘ t’ test. Dose injected per 
mice-2.6 mg.   
T
formulations F1 was selected for stability studies on 
the basis of their high cumulative % drug release 
studies. The stability studies were carried out at 
25°C/60% RH and 40°C/75% RH for all the selected 
formulations up to 6 months. For every 1 months time 
interval the tablets were analyzed for in vitro 
disintegration time. These formulations showed not 
much variation in any parameter. The accelerated 
stability study shows no degradation in all the tablet 
formulations during study. The combination 
formulation of Isoniazid and Rifampicin (F-1) was 
also studied for bioavailability in the blood. The 
dispersible tablets was found to be 19.22 % of the 
injected dose, whereas the concentration of pure 
Isoniazid was 14.82 % in the blood. Similarly, the 
average bioavailability of Rifampicin from 
combination dispersible tablets (F-5) was found to be 
17.44 % of the injected dose in blood, whereas the 
concentration of pure Isoniazid was 13.37 % in the 
blood. Dispersible formulations were compared with 
pure Isoniazid, Rifampicin group applying Student ‘t’ 
test, the statistical results showed that the probability 
value was highly significant P<0.0001 (Table  8). 
These results reveal that dispersible formulations 
showed preferential drug bioavailability in the blood. 
It was also revealed that as compared to pure drug, 
higher concentration of drug was bio-available to the 
blood after administering the dose in form of 
dispersible formulations.  
Thus, it can be concluded that dispersible table can be 
formulated by employi
tion
containing disintegrants such as crosscarmellose 
sodium (Ac-di-sol), and Polyplasdone XL. Further, 
Long term stability studies and in-vivo studies need to 
be carried out for establishing the existing products. 
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